Devic症候群治疗市场按治疗方法、通路和最终用户划分 - 全球预测 2025-2032

预计到 2032 年，德维克症候群治疗市场将成长至 3.2102 亿美元，复合年增长率为 4.82%。

清晰而实用地概述了影响德维克综合征治疗决策的临床实际情况、相关人员的优先事项和操作要务。

本执行摘要全面概述了德维克综合征治疗领域的最新临床和商业性进展，整合了临床试验进展、治疗模式、监管里程碑以及面向整个医疗价值链相关人员的营运考虑。报告首先阐述了该疾病的临床异质性和不断发展的治疗标准，然后探讨了新型标靶治疗和现有疗法如何重塑患者治疗路径和医保支付方的互动模式。分析过程中，重点在于提供切实可行的见解，以支援产品开发、报销策略和临床专案协调。

科学突破、适应性监管途径和医疗服务创新将如何共同重塑德维克综合症的治疗选择和获取模式？

受科学进步、监管变革和医疗服务模式演变的推动，德维克综合症的治疗格局正在经历变革性变化，这些因素共同重塑了人们对治疗的预期和投资重点。单株抗体研发的突破性进展提供了特异性机制的治疗选择，以取代传统的广谱免疫抑制疗法，促使临床医生重新思考治疗顺序和长期管理策略。同时，诊断特异性的提高和疾病表型早期识别使得更有针对性地启动高效疗法成为可能，并正在重塑临床试验的患者群体。

评估2025年美国关税调整对营运和采购的影响及其对治疗药物供应和合约经济性的下游影响

美国在2025年实施的关税调整和贸易政策变化，为全球供应链和筹资策略引入了新的变数，影响着与德维克症候群相关的治疗方法的研发和分销。依赖跨境采购活性药物成分、生物製药或输注装置的製造商和经销商面临成本结构波动和前置作业时间变化，这会影响其定价策略以及与支付方和医院的合约谈判。儘管治疗方法的临床提案仍然是支付方考虑的首要因素，但不断上涨的供应链成本可能会限制药物被纳入健保目录，并需要重新评估健康经济模型以反映不断上涨的采购成本。

详细的細項分析，阐述了治疗方法、通路和终端用户环境如何相互作用，从而决定临床路径和商业性执行。

细分市场分析揭示了不同治疗类型、分销管道和终端用户环境之间的显着差异，这些差异共同塑造了临床路径和商业性策略。按治疗类型划分，糖皮质激素仍然是急性期治疗的基础选择，分为静脉注射和口服两种剂型，这决定了给药方式和监测要求。Azathioprine和Mycophenolate Mofetil等免疫抑制剂继续作为维持治疗药物发挥作用，其安全性监测和依从性要求各不相同。单株抗体，特别是Eculizumab和伊奈利珠单抗，透过标靶机制重新定义了长期疾病管理，这需要低温运输物流和专门的报销通讯协定。血浆置换疗法采用自动化和手动两种方式进行，对人员配备、设备和疗程安排都有影响。包括疼痛管理和物理治疗在内的支持性护理对于整体性的患者照护和优化生活品质至关重要。

区域监管差异、医疗保健融资模式和临床能力差异如何影响德维兹症候群治疗的可近性和接受度

区域趋势在治疗方法研发和准入的策略规划中发挥核心作用，因为它们深刻影响临床实践模式、监管方式和支付方环境。在美洲，先进的法规结构和集中的临床专家中心促进了高效治疗方法的早期应用，而报销谈判和预算限制则决定了疗法能否广泛普及。该地区的医疗管理系统和综合医疗网络通常需要强有力的疗效比较证据和真实世界结果，以支持药物目录的纳入和使用管理政策。

深入了解以临床差异化、卓越营运和综合患者支援服务为核心的竞争策略，这些策略定义了德维克综合症治疗领域的市场领导地位。

德维克症候群治疗领域的竞争格局呈现出多元化的特点，既有成熟的非专利免疫抑制剂，也有拥有特化生物製药的新兴企业，以及提供输液和血浆置换服务供应商。各企业的关键策略正趋向于差异化的临床证据、持久的安全性以及能够降低治疗障碍的综合患者支持服务。生物製药申办方致力于证明其长期疗效和降低復发率，同时投资扩大生产规模、提高分销可靠性，并与支付方协商基本契约。这些申办者也优先收集真实世界证据，以证明其比较优势并支持扩大适应症。

为产业领导者提供切实可行的策略行动，将证据产生、供应链韧性和个人化配送连结起来，以确保疗法的持续推广应用。

行业领导者应优先采取一系列果断行动，将科学进步转化为永续的临床和商业性成功。首先，应协调临床开发和核准后证据产生计划，以满足支付方和临床医生对长期疗效和相对有效性的期望，从而降低报销谈判中的不确定性，并支持适应症差异化。其次，应透过供应商多元化、关键製造地地域多角化以及实施关税应对计划来增强供应链韧性，以减轻采购中断的影响，确保治疗的连续性。

我们采用稳健的多来源调查方法，结合同侪审查的证据、相关利益者访谈、供应链分析和专家检验，以确保可靠性和实用性。

本分析的调查方法整合了多方面的资料检验和严格的检验程序，以确保其可靠性和对决策者的相关性。此方法首先对同行评审的临床文献、监管核准和已发表的临床试验结果进行全面审查，以阐明治疗机制、疗效终点和安全性讯号。此外，还对治疗指南和支付方决策框架进行了检验，以了解报销标准和临床应用驱动因素。

简洁扼要的总结强调了需要采取综合证据策略、提高营运韧性以及製定在地化的准入计划，才能充分发挥治疗的潜力。

总之，随着生物目标、不断演变的监管机制和适应性护理模式的融合，德维克氏症候群的治疗和商业格局正处于一个关键的转折点，这些因素共同重新定义了治疗标准。相关人员必须权衡高效、针对特异性机制的治疗方法的潜力与分销、报销和长期监测等方面的实际考虑。供应链和政策趋势凸显了业务营运中韧性和前瞻性的重要性，而市场区隔和区域动态则强调了製定客製化市场进入策略的必要性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 针对视神经脊髓炎的治疗方法，随着特异性和安全性的提高，其应用迅速普及。
• 将真实世界数据和病患登记资讯整合到德维克症候群的临床决策支援系统中
• 针对 Devic 症候群的水通道蛋白 4标靶治疗的单株抗体研发管线获得了越来越多的投资。
• 生物相似药和新型生物製药的出现，正在推动 Devic 症候群治疗领域的成本竞争。
• 远端医疗和远端监测设备在脊髓炎患者照护中日益重要。
• 扩大基因和生物标记研究，以实现针对德维克症候群的个人化治疗策略。
• 製药公司和生物技术公司之间的合作伙伴关係加速了德维克综合征治疗领域的创新。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 德维克症候群治疗市场（依治疗方法划分）

• 皮质类固醇
  • 静脉注射
  • 口服
• 免疫抑制剂
  • Azathioprine
  • Mycophenolate Mofetil
• 单株抗体
  • Eculizumab
  • 伊尼利珠单抗
• 血浆置换
  • 自动的
  • 手动的
• 支持性护理
  • 疼痛管理
  • 物理治疗

9. 德维克综合症治疗市场（按分销管道划分）

• 医院药房
• 网路药房
• 零售药房

第十章 依最终用户分類的德维克症候群治疗市场

• 家庭医疗保健
• 医院
• 专科诊所

第十一章 Devic 症候群治疗市场：按地区划分

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十二章 德维克症候群治疗市场（按组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

13. 各国德维克氏症候群治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十四章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Alexion Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Viela Bio, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.

The Devic's Syndrome Treatment Market is projected to grow by USD 321.02 million at a CAGR of 4.82% by 2032.

A clear and actionable overview that frames clinical realities, stakeholder priorities, and operational imperatives shaping Devic's syndrome therapeutic decision-making

This executive summary introduces a consolidated briefing on current clinical and commercial developments in Devic's syndrome therapeutics, synthesizing clinical trial progress, treatment paradigms, regulatory milestones, and operational considerations for stakeholders across the healthcare value chain. The narrative begins by framing the clinical heterogeneity of the disorder and the evolving standards of care, then moves into how novel targeted therapies and established approaches are reshaping patient pathways and payer dialogues. Throughout the analysis, emphasis is placed on actionable intelligence that supports product development, reimbursement strategy, and clinical program alignment.

Given the multiplicity of therapeutic classes under evaluation, the introduction foregrounds the mechanisms of action, delivery modalities, and care settings that define decision points for clinicians, hospital systems, and specialty clinics. The briefing contextualizes recent approvals and label expansions alongside utilization patterns seen in hospital pharmacies, retail and online distribution channels, and home healthcare programs. It also outlines key stakeholder motivations, including clinicians' priorities for durable efficacy and safety, payers' concerns about cost-effectiveness, and patients' needs for reduced treatment burden.

As an opening synthesis, the introduction clarifies scope, highlights the imperative for integrated cross-functional planning, and sets the stage for subsequent sections that examine landscape shifts, policy impacts, segmentation insights, regional dynamics, competitive positioning, recommendations, and the research methods applied. This structured approach ensures readers can translate evidence into strategy while maintaining clarity on clinical realities and operational constraints.

How scientific breakthroughs, adaptive regulatory pathways, and care delivery innovations are collectively reshaping therapy selection and access dynamics for Devic's syndrome

The therapeutic landscape for Devic's syndrome is undergoing transformative shifts driven by scientific advances, regulatory changes, and evolving care delivery models that together redefine treatment expectations and investment priorities. Breakthroughs in monoclonal antibody development have introduced mechanism-specific options that challenge prior reliance on broad immunosuppression, prompting clinicians to rethink treatment sequencing and long-term management strategies. In parallel, improvements in diagnostic specificity and earlier identification of disease phenotypes are enabling more targeted initiation of high-efficacy therapies while reshaping enrollment pools for clinical studies.

Concurrently, regulatory pathways have adapted to accommodate accelerated reviews for therapies demonstrating substantial benefit on validated clinical endpoints, which has accelerated time-to-market for select biologics. This regulatory momentum has induced greater competition among sponsors to secure label differentiation through head-to-head studies, real-world evidence generation, and biomarker-driven subpopulation data. At the delivery level, the expansion of home-based care and scaled access to infusion services outside traditional hospital settings have altered distribution and reimbursement conversations, compelling payers and providers to negotiate new care models that balance cost, convenience, and clinical oversight.

Taken together, these shifts create both strategic risk and opportunity: organizations that invest in differentiated evidence strategies, robust post-approval surveillance, and adaptive distribution partnerships will be better positioned to secure clinician adoption and payer acceptance, while those slow to align with the new clinical paradigms may face intensified access barriers and constrained uptake.

Assessing the operational and procurement consequences of United States tariff adjustments in 2025 and their downstream effects on therapeutic availability and contractual economics

Recent tariff developments and trade policy adjustments implemented by the United States in 2025 have introduced new variables into global supply chains and procurement strategies that affect the development and distribution of therapies relevant to Devic's syndrome. Manufacturers and distributors that rely on cross-border sourcing for active pharmaceutical ingredients, biologic components, or infusion devices have encountered shifting cost structures and lead-time variability, which in turn influence pricing strategies and contracting conversations with payers and hospitals. While the clinical value proposition of a therapy remains primary in payer deliberations, increased supply-chain costs can constrain formulary placements and require revised health-economic models to reflect higher procurement expenses.

In response, several manufacturers have prioritized supply-chain resilience by diversifying sourcing, regionalizing production hubs, and negotiating tariff-mitigation clauses into supplier contracts. These operational adjustments are particularly pronounced for platform-dependent products such as monoclonal antibodies and plasm a-exchange consumables, where tight tolerances and specialized manufacturing inputs make near-term substitution challenging. Moreover, distribution partners and hospital pharmacies are reassessing inventory strategies to buffer against transit disruptions, which has implications for working capital and on-hand availability for patients requiring urgent treatment initiation.

Ultimately, the cumulative impact of tariff policy in 2025 has emphasized the need for integrated commercial planning that incorporates trade policy scenarios into procurement, contracting, and pricing models. Stakeholders who proactively model tariff-driven contingencies and engage in collaborative sourcing partnerships will be better equipped to preserve uninterrupted access to critical therapies for patients living with Devic's syndrome.

Detailed segmentation insights explaining how treatment modalities, distribution channels, and end-user settings interact to determine clinical pathways and commercial execution

Segmentation analysis reveals divergent dynamics across treatment types, distribution channels, and end-user settings that together shape clinical pathways and commercial approaches. By treatment type, corticosteroids remain a foundational acute management option and are sub-classified into intravenous and oral formulations that inform administration setting and monitoring requirements; immunosuppressants such as azathioprine and mycophenolate mofetil continue to serve maintenance roles with distinct safety monitoring and adherence profiles; monoclonal antibodies, notably eculizumab and inebilizumab, are redefining long-term disease control considerations through targeted mechanisms that demand cold-chain logistics and specialized reimbursement protocols; plasma exchange appears in both automated and manual modalities with implications for staffing, capital equipment, and session scheduling; and supportive therapy, which encompasses pain management and physiotherapy, remains indispensable for holistic patient care and quality-of-life optimization.

When examining distribution channels, hospital pharmacies, online pharmacies, and retail pharmacies present unique advantages and limitations that affect access, adherence, and continuity of care. Hospital pharmacies facilitate complex administration and immediate clinical oversight, online pharmacies offer convenience and potentially expanded geographic reach with unique regulatory compliance needs, and retail pharmacies serve as critical touchpoints for patient counseling and repeat dispensing. From an end-user perspective, home healthcare, hospitals, and specialty clinics each operate with distinct operational constraints and reimbursement frameworks. Home healthcare supports decentralization and patient convenience but requires rigorous care coordination and safety protocols; hospitals enable acute management and multidisciplinary collaboration; and specialty clinics concentrate expertise and may accelerate adoption of novel therapies through focused clinician experience and structured follow-up.

These segmentation layers interact to influence clinical decision-making and commercial execution. For instance, a monoclonal antibody requiring infusion and specialized monitoring is typically routed through hospital or specialty clinics and dispensed via hospital pharmacy channels, whereas oral corticosteroids and common immunosuppressants may traverse retail and online pharmacies, enabling distributed access. Understanding these interdependencies is essential for aligning manufacturing, distribution, and patient-support programs with real-world care pathways.

How regional regulatory diversity, healthcare financing models, and clinical capacity variations shape differential access and adoption of therapies for Devic's syndrome

Regional dynamics exert substantial influence on clinical practice patterns, regulatory approaches, and payer environments, and they therefore play a central role in strategic planning for therapy development and access. In the Americas, advanced regulatory frameworks and concentrated centers of clinical expertise drive early adoption of high-efficacy interventions, while reimbursement negotiations and budgetary constraints shape pathways to broad access. Managed care systems and integrated delivery networks in this region frequently demand robust comparative effectiveness evidence and real-world outcomes to support formulary inclusion and utilization management policies.

Europe, Middle East & Africa presents a heterogeneous landscape where national regulatory agencies, diverse healthcare financing models, and varying degrees of clinical capacity lead to differentiated adoption curves. In some European markets, centralized pricing and health-technology assessment processes require comprehensive evidence dossiers and health-economic modeling; conversely, markets within the Middle East and Africa may experience constrained specialty care infrastructure, necessitating tailored distribution approaches and capacity-building initiatives to improve diagnosis and treatment delivery.

In the Asia-Pacific region, rapid regulatory modernization in several markets is accelerating the entry of innovative therapies, while distinct payer priorities and out-of-pocket payment models in other jurisdictions influence patient access and affordability. Supply-chain proximity within Asia-Pacific can be advantageous for manufacturers seeking regional manufacturing hubs, but local regulatory requirements, importation rules, and country-specific clinical expectations require adaptive regulatory and market-access strategies. Across all regions, coordinated stakeholder engagement, evidence generation aligned with local decision-makers, and flexible delivery models will be critical to bridging clinical innovation and patient access.

Insight into competitive strategies where clinical differentiation, operational excellence, and integrated patient-support services determine market leadership in Devic's syndrome care

Competitive positioning within the Devic's syndrome therapeutic landscape is characterized by a mix of established generic immunosuppressants, specialized biologic entrants, and service providers offering infusion and plasma exchange capabilities. Key corporate strategies are clustering around differentiated clinical evidence, durable safety profiles, and integrated patient-support services that reduce treatment friction. Biologic sponsors focus on demonstrating long-term efficacy and reduced relapse rates while investing in manufacturing scale-up, distribution reliability, and value-based contracting conversations with payers. These sponsors also prioritize real-world evidence collection to substantiate comparative benefit and inform label expansions.

Manufacturers of traditional immunosuppressants and corticosteroids emphasize longstanding clinical familiarity, cost-effectiveness in certain care scenarios, and well-understood safety-monitoring pathways. Their commercial approach tends to concentrate on optimizing supply continuity, ensuring broad distribution through hospital and retail channels, and supporting clinicians with pragmatic guidance for maintenance therapy. Providers of plasma exchange technologies and services are differentiating through automation, capacity-building partnerships with hospitals and specialty clinics, and alignment with hybrid care models that shift certain services closer to the patient.

Across the competitive set, successful firms are those that integrate clinical differentiation with operational excellence in cold-chain logistics, payer engagement, and clinician education. Strategic collaborations between biologic developers and service providers that streamline administration and monitoring pathways are emerging as a critical axis for delivering comprehensive value to healthcare systems and patients alike.

A pragmatic set of strategic actions for industry leaders to link evidence generation, supply-chain resilience, and tailored distribution to secure durable therapy adoption

Industry leaders should prioritize a sequence of decisive actions to convert scientific advances into sustainable clinical and commercial success. First, align clinical development and post-approval evidence-generation plans to address payer and clinician expectations for long-term outcomes and comparative effectiveness, thereby reducing uncertainty during reimbursement negotiations and supporting label differentiation. Second, invest in supply-chain resilience by diversifying suppliers, regionalizing critical manufacturing nodes, and implementing tariff-contingency planning to mitigate procurement disruptions and preserve treatment continuity.

Third, design distribution and patient-support programs that reflect segmentation realities: tailor pharmacy pathways for oral and infusion therapies, develop robust home healthcare protocols where appropriate, and partner with specialty clinics to accelerate clinician familiarity and patient monitoring. Fourth, engage proactively with regional health authorities and payers to co-create value frameworks that recognize both clinical benefit and system-level efficiencies, employing real-world data to substantiate health-economic narratives. Fifth, foster collaborative partnerships among biologic developers, device and service providers, and clinical centers to streamline administration workflows and reduce patient burden.

By executing these priorities in a coordinated manner-linking clinical evidence, operational readiness, and payer engagement-industry leaders can increase the probability of durable adoption while demonstrating responsible stewardship of healthcare resources.

A robust multi-source methodology combining peer-reviewed evidence, stakeholder interviews, supply-chain analysis, and expert validation to ensure credible and actionable insights

The research methodology underpinning this analysis integrates multi-source data triangulation with rigorous validation steps designed to ensure credibility and relevance for decision-makers. The approach began with a comprehensive review of peer-reviewed clinical literature, regulatory approvals, and published clinical-trial results to map therapeutic mechanisms, efficacy endpoints, and safety signals. This literature review was complemented by an examination of treatment guidelines and payer decision frameworks to understand reimbursement criteria and clinical adoption drivers.

Primary data collection included structured interviews with clinicians, hospital pharmacists, specialty clinic managers, and distribution executives to capture frontline perspectives on treatment selection, administration logistics, and patient-support needs. Supply-chain analyses leveraged publicly available manufacturing and trade data to assess potential vulnerabilities and the operational impact of policy shifts. Where applicable, real-world evidence sources and registry data were consulted to contextualize treatment patterns and durability of response outside controlled trial environments.

All findings underwent cross-validation through expert panel review and sensitivity checks to reconcile divergent stakeholder viewpoints. Analytical techniques combined qualitative thematic analysis with scenario planning to surface strategic implications and actionable recommendations. Ethical research practices, transparency in source attribution, and adherence to data privacy standards were maintained throughout the process to ensure robustness and reproducibility of insights.

A concise synthesis emphasizing the need for integrated evidence strategies, operational resilience, and regionally adaptive access plans to realize therapeutic potential

In conclusion, the therapeutic and commercial environment for Devic's syndrome is in a period of meaningful transition as targeted biologics, evolving regulatory mechanisms, and adaptive care models converge to redefine standards of care. Stakeholders must reconcile the promise of high-efficacy, mechanism-specific therapies with practical considerations around distribution, reimbursement, and long-term monitoring. Supply-chain and policy developments have amplified the importance of resilience and operational foresight, while segmentation and regional dynamics underscore the need for customized market-access approaches.

Successful navigation of this landscape requires integrated strategies that marry rigorous evidence generation with pragmatic delivery solutions, regional regulatory acumen, and sustained payer engagement. Organizations that invest in comprehensive post-approval data collection, flexible distribution networks, and collaborative partnerships across the care continuum will be positioned to translate scientific innovation into meaningful patient outcomes and system-level value. Ultimately, the intersection of clinical differentiation and operational excellence will determine which therapies gain broad clinician acceptance and secure reliable patient access.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rapid adoption of neuromyelitis optica therapies with improved specificity and safety profiles
• 5.2. Integration of real-world evidence and patient registries in clinical decision support for Devic's syndrome
• 5.3. Increasing investment in monoclonal antibody pipeline focusing on aquaporin-4 targeted treatments for Devic's syndrome
• 5.4. Emergence of biosimilars and novel biologics driving cost competition in Devic's syndrome management
• 5.5. Growing significance of telemedicine and remote monitoring devices for neuromyelitis optica patient care
• 5.6. Expansion of genetic and biomarker research enabling personalized treatment strategies for Devic's syndrome
• 5.7. Collaborative partnerships between pharma and biotech accelerating Devic's syndrome therapy innovation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Devic's Syndrome Treatment Market, by Treatment Type

• 8.1. Corticosteroids
  • 8.1.1. Intravenous
  • 8.1.2. Oral
• 8.2. Immunosuppressants
  • 8.2.1. Azathioprine
  • 8.2.2. Mycophenolate Mofetil
• 8.3. Monoclonal Antibodies
  • 8.3.1. Eculizumab
  • 8.3.2. Inebilizumab
• 8.4. Plasma Exchange
  • 8.4.1. Automated
  • 8.4.2. Manual
• 8.5. Supportive Therapy
  • 8.5.1. Pain Management
  • 8.5.2. Physiotherapy

9. Devic's Syndrome Treatment Market, by Distribution Channel

• 9.1. Hospital Pharmacies
• 9.2. Online Pharmacies
• 9.3. Retail Pharmacies

10. Devic's Syndrome Treatment Market, by End User

• 10.1. Home Healthcare
• 10.2. Hospitals
• 10.3. Specialty Clinics

11. Devic's Syndrome Treatment Market, by Region

• 11.1. Americas
  • 11.1.1. North America
  • 11.1.2. Latin America
• 11.2. Europe, Middle East & Africa
  • 11.2.1. Europe
  • 11.2.2. Middle East
  • 11.2.3. Africa
• 11.3. Asia-Pacific

12. Devic's Syndrome Treatment Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Devic's Syndrome Treatment Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Analysis
  • 14.3.1. Alexion Pharmaceuticals, Inc.
  • 14.3.2. F. Hoffmann-La Roche Ltd.
  • 14.3.3. Viela Bio, Inc.
  • 14.3.4. Chugai Pharmaceutical Co., Ltd.
  • 14.3.5. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 9. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GCC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPEAN UNION DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. BRICS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. G7 DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. NATO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 26. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DEVIC'S SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 200. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 201. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 242. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 243. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 244. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 245. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
• TABLE 246. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
• TABLE 247. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 248. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 249. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
• TABLE 250. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 256. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 257. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 260. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 261. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 262. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 263. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
• TABLE 264. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
• TABLE 265. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 266. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 271. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 272. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 273. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 274. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 275. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 278. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 279. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 280. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 281. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2025-2032 (USD MILLION)
• TABLE 287. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 288. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 289. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 290. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 291. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 292. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 293. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 294. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 295. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 298. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 299. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
• TABLE 300. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
• TABLE 301. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
• TABLE 302. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
• TABLE 303. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY M